Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Sensei Biotherapeutics (NASDAQ:SNSE), a clinical stage biotech company developing next-generation cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO John Celebi will conduct one-on-one investor meetings on September 8, 2025. The company's on-demand corporate presentation will be available starting September 5, 2025, at 7:00 a.m. ET. Investors can access the webcast replay in the Investors section of Sensei's website for approximately 90 days after the event.
Sensei Biotherapeutics (NASDAQ:SNSE), azienda biotech in fase clinica che sviluppa terapie oncologiche di nuova generazione, ha annunciato la sua partecipazione alla 27ª Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright.
Il CEO John Celebi terrà incontri one-to-one con gli investitori il 8 settembre 2025. La presentazione aziendale on-demand sarà disponibile a partire dal 5 settembre 2025, alle 7:00 ET. Gli investitori potranno visualizzare la replica webcast nella sezione Investors del sito di Sensei per circa 90 giorni dopo l'evento.
Sensei Biotherapeutics (NASDAQ:SNSE), una empresa biotecnológica en fase clínica que desarrolla terapias oncológicas de nueva generación, anunció su participación en la 27.ª Conferencia Anual Global de Inversión de H.C. Wainwright.
El CEO John Celebi realizará reuniones individuales con inversores el 8 de septiembre de 2025. La presentación corporativa bajo demanda estará disponible a partir del 5 de septiembre de 2025, a las 7:00 a.m. ET. Los inversores podrán acceder a la repetición del webcast en la sección Investors del sitio web de Sensei durante aproximadamente 90 días tras el evento.
Sensei Biotherapeutics (NASDAQ:SNSE)는 차세대 암 치료제를 개발하는 임상 단계 바이오텍으로, H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다.
CEO John Celebi는 2025년 9월 8일에 투자자와의 일대일 미팅을 진행합니다. 온디맨드 기업 발표는 2025년 9월 5일 오전 7:00(동부 표준시)부터 이용 가능하며, 투자자들은 행사 후 약 90일 동안 Sensei 웹사이트의 Investors 섹션에서 웨비스트 재방송을 볼 수 있습니다.
Sensei Biotherapeutics (NASDAQ:SNSE), une société biotechnologique en phase clinique développant des thérapies oncologiques de nouvelle génération, a annoncé sa participation à la 27e conférence annuelle mondiale sur l'investissement organisée par H.C. Wainwright.
Le PDG John Celebi tiendra des réunions individuelles avec des investisseurs le 8 septembre 2025. La présentation d'entreprise à la demande sera disponible à partir du 5 septembre 2025, à 7h00 ET. Les investisseurs pourront accéder au replay du webcast dans la section Investors du site de Sensei pendant environ 90 jours après l'événement.
Sensei Biotherapeutics (NASDAQ:SNSE), ein Biotech-Unternehmen in der klinischen Phase, das neuartige Krebstherapeutika entwickelt, gab seine Teilnahme an der 27. jährlichen Global Investment Conference von H.C. Wainwright bekannt.
CEO John Celebi wird am 8. September 2025 Einzelgespräche mit Investoren führen. Die On-Demand-Unternehmenspräsentation ist ab dem 5. September 2025, 7:00 Uhr ET verfügbar. Investoren können die Webcast-Wiedergabe etwa 90 Tage nach der Veranstaltung im Bereich Investors auf der Sensei-Website abrufen.
- None.
- None.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025.
An on-demand corporate presentation will be available here on September 5, 2025, at 7:00 a.m. ET. A replay of the webcast will be available in the Investors section of the Sensei website for approximately 90 days following the event.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor and Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When is Sensei Biotherapeutics (SNSE) presenting at the H.C. Wainwright Conference 2025?
How can investors access Sensei Biotherapeutics' H.C. Wainwright conference presentation?
What is Sensei Biotherapeutics' (SNSE) main business focus?
Who will represent Sensei Biotherapeutics at the H.C. Wainwright Conference?
